Printer Friendly


Dipharma has strengthened its pipeline of improved formulations for the treatment of patients suffering from inborn errors of metabolism. Dipharma S.A. announces the successful development of a new, fast dissolving formulation of Carglumic acid tablets stable at room temperature.

Carglumic acid is a key therapeutic tool in the management of rare, life threatening inborn metabolic disorders affecting the urea cycle; as such it was a natural candidate for the Company's products portfolio.

Dipharma S.A. also announces the filing of a patent application claiming new fast dissolving and stable tablet formulations of Carglumic acid, together with the proprietary technology developed to improve the product stability, without modifying the pharmaceutical form the patients are familiar to.

Carglumic acid formulation is the fourth Dipharma product approaching the market: Diterin (sapropterin dihydrochloride 100 mg tabs) has already been approved in South Korea and Russia for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU), Miglustat (miglustat 100 mg caps) was submitted in the USA through an abbreviated new drug application (ANDA) in 2016 for the treatment of Gaucher disease and Disanit[R] (nitisinone capsules) was submitted in EU in the last quarter of 2016 for the treatment of hereditary tyrosinemia type I. Dipharma also confirms that the development of several other products for the treatment of rare metabolic diseases is on- going.

About Carglumic acid

Carglumic acid tablets 200mg (Carbaglu) is a prescription drug used in the management of high ammonia levels due to rare inborn errors of metabolism affecting the urea cycle. For more information on urea cycle disorders, visit

About Dipharma

Dipharma S.A. is a Swiss pharmaceutical company specialized in developing medicines for rare diseases. Dipharma S.A. is part of a third-generation group of family companies that have grown to a global presence. With a portfolio of products for the treatment of Phenylketonuria, Gaucher Disease, Niemann Pick Type C, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma SA works to provide solutions for people affected by inborn metabolic diseases at an affordable cost and with a global reach.

For more information, visit

COPYRIGHT 2017 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Date:May 1, 2017
Next Article:SHARP MAKES [pounds sterling]9 MILLION INVESTMENT.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters